BET 4: Management of adult patients with icatibant in hereditary angioedema

Emergency Medicine Journal

Volumn 28, Issue 8, 2011, Pages 720-721

  Drake, David ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ICATIBANT; PLACEBO; TRANEXAMIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; DRUG DERIVATIVE;

ANGIONEUROTIC EDEMA; CLINICAL RESEARCH; DISEASE SEVERITY; DRUG EFFICACY; EMERGENCY MEDICINE; HUMAN; NOTE; PLACEBO EFFECT; PRIORITY JOURNAL; TREATMENT OUTCOME; ADOLESCENT; EVIDENCE BASED MEDICINE; FEMALE; REVIEW;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ANGIOEDEMAS, HEREDITARY; BRADYKININ; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS;

EID: 79960764018     PISSN: 14720205     EISSN: 14720213     Source Type: Journal    
DOI: 10.1136/emermed-2011-200396-4     Document Type: Note

References (1)

1. Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykinin receptor antagonist, in hereditary angioedema. N Engl J Med 2010;363:532-41.